Evidence map›Paper›PMID 38743957›Full record

ArticleRevista da Escola de Enfermagem da U S P2024

Nanocomposites used in the treatment of skin lesions: a scoping review.

Wevernilson Francisco de Deus, Camylla Layanny Soares Lima, Ana Luiza Barbosa Negreiros, Phellype Kayyaã da Luz, Raylane da Silva Machado, Grazielle Roberta Freitas da Silva

Abstract readScoping Review
In one paragraph

Article in Revista da Escola de Enfermagem da U S P, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wevernilson Francisco de DeusUniversidade Federal do Piauí, Programa de Pós Graduação em Enfermagem, Teresina, PI, Brazil.ORCID 0000-0002-2363-6859
Camylla Layanny Soares LimaUniversidade Federal do Piauí, Programa de Pós Graduação em Enfermagem, Teresina, PI, Brazil.ORCID 0000-0001-5015-6597
Ana Luiza Barbosa NegreirosUniversidade Federal do Piauí, Programa de Pós Graduação em Enfermagem, Teresina, PI, Brazil.ORCID 0000-0002-8313-0403
Phellype Kayyaã da LuzUniversidade Federal do Piauí, Teresina, PI, Brazil.ORCID 0000-0002-9320-957X
Raylane da Silva MachadoUniversidade Federal do Piauí, Teresina, PI, Brazil.ORCID 0000-0002-8682-6481
Grazielle Roberta Freitas da SilvaUniversidade Federal do Piauí, Programa de Pós Graduação em Enfermagem, Teresina, PI, Brazil.ORCID 0000-0002-0402-6801

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo map the nanocomposites used in the treatment of skin lesions.

methodA scoping review, according to the Joanna Briggs Institute methodology, carried out on eight databases, a list of references and Google Scholar to answer the question: "Which nanocomposites are used as a cover for the treatment of skin lesions?". Two independent reviewers selected the final sample using inclusion/exclusion criteria using the EndNote® and Rayyan programs. Data was extracted using an adapted form and reported using the PRISMA checklist extension, and the protocol was registered in the Open Science Framework (OSF).

results21 articles were selected, with nanofibers, nanogels and nanomembranes as the nanocomposites described in wound healing, alone or in association with other therapies: negative pressure and elastic. Silver nanomaterials stand out in accelerating healing due to their antimicrobial and anti-inflammatory action, but caution should be exercised due to the risk of cytotoxicity and microbial resistance.

conclusionNanocomposites used in wound treatment are effective in accelerating healing and reducing costs, and the addition of bioactives to nanomaterials has added extra properties that contribute to healing.

Indexed as

NanocompositesSkin DiseasesWound HealingAnti-Infective AgentsHumansNanofibersSilverAnti-Infective AgentsSilver

Identifiers

PMID38743957
PMCPMC11110158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.